BOTHELL, WA--(Marketwire - November 02, 2010) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, will report third quarter 2010 financial results after the NASDAQ Global Market closes on Tuesday, November 9, 2010. Subsequently, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time), J. David Boyle II, AVI’s Interim President and Chief Executive Officer, and Chief Financial Officer, and Stephen B. Shrewsbury, AVI’s Senior Vice President and Chief Medical Officer, will host a conference call to discuss third quarter 2010 financial results and to provide a corporate update.
The conference call may be accessed by dialing 800.573.4842 for domestic callers and 617.224.4327 for international callers. The passcode for the call is 29591329 and please specify to the operator that you would like to join the “AVI BioPharma third quarter 2010 earnings call.” The conference call will be webcast live under the events section of AVI’s website at www.avibio.com, and will be archived there following the call. Please connect to AVI’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI’s technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging our highly differentiated RNA antisense-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including one in the clinical development stage for the treatment of Duchenne muscular dystrophy. For more information, visit www.avibio.com.
